The article plays up the HCQ adverse effects on heart/cardiovascular patients and uses this basis to require that all patients receiving HCQ be in hospital, which is not what Dr. Zelenko advocates. He tries to treat all his patients early and at home with HCQ and has them monitored in this state by his staff. Not all patients will have pre-existing heart/cardiovascular issues. It looks to me to be another excuse not in the best interest of the patient.
Professor Raoult of France says the same thing.
Professor Didier Raoult Releases the Results of a New Hydroxychloroquine Treatment Study on 1061 Patients
CovidExit.com ^ | 04/10/2020
Posted on 4/11/2020, 2:05:33 AM by SeekAndFind
The new study, of which the abstract was released today, was performed at IHU Méditerranée Infection, Marseille, France. A cohort of 1061 COVID-19 patients, treated for at least 3 days with the Hydroxychloroquine-Azithromycin (HCQ-AZ) combination and a follow-up of at least 9 days was investigated.
Key findings are:
No cardiac toxicity was observed.
A good clinical outcome and virological cure was obtained in 973 patients within 10 days (91.7%).
A poor outcome was observed for 46 patients (4.3%); 10 were transferred to intensive care units, 5 patients died (0.47%) (74-95 years old) and 31 required 10 days of hospitalization or more.
The authors conclude that:
“The HCQ-AZ combination, when started immediately after diagnosis, is a safe and efficient treatment for COVID-19, with a mortality rate of 0.5%, in elderly patients. It avoids worsening and clears virus persistence and contagiosity in most cases.”
I wonder if in treating before things get dire, if a lower dose and possibly duration is used and if that contributes to less cardiac risk. I really wish there was more info avail on what dosages are being used, at what course in treatment, in conjunction with what (azith, zinc) as well as what conditions and other meds patients have and the outcome for each.